CA 125 modifications throughout menstrual cycle and following gnrh-analog administration to diagnose endometriosis as cause of chronic pelvic pain. A prospective controlled study

Journal of Endometriosis

Volumn 3, Issue 3, 2011, Pages 151-158

  Venturella, Roberta ^a   D'Alessandro, Pietro ^a   Gallo, Francesco ^a   Morelli, Michele ^a   Zullo, Fulvio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

CA 125; Chronic pelvic pain; Diagnosis; Endometriosis; GnRH analog

Indexed keywords

CA 125 ANTIGEN; LEUPRORELIN;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENDOMETRIOSIS; FEMALE; FEMALE INFERTILITY; FOLLICULAR PHASE; HISTOLOGY; HUMAN; LAPAROSCOPY; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PELVIS PAIN SYNDROME; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE;

EID: 84255196949     PISSN: 20359969     EISSN: 2036282X     Source Type: Journal    
DOI: 10.5301/JE.2011.8911     Document Type: Article

References (38)

1. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997; 24: 235-58.
2. Barbieri RL. Primary Gonadotropin-Releasing Hormone Agonist Therapy for Suspected Endometriosis: a Nonsurgical Approach to the Diagnosis and Treatment of Chronic Pelvic Pain. Am J Manag Care 1997; 3: 285-9.
3. Kennedy S, Bergqvist A, Chapron C, et al. ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20:2698-704.
4. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67: 817-21.
5. Bedaiwy MA, Falcone T, Sharma RK, et al. Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Hum Reprod 2002; 17: 426-31.
6. Busacca M, Chiaffarino F, Candiani M, et al. Determinants of long-term clinically detected recurrence rates of deep, ovarian and pelvic endometriosis. Am J Obstet Gynecol 2006; 195: 426-32.
7. Exacoustos C, Zupi E, Amadio A, et al. Recurrence of endometriomas after laparoscopic removal: sonographic and clinical followup and indication for second surgery. J Minim Invasive Gynecol 2006; 13: 281-8.
8. Kikuchi I, Takeuchi H, Kitade M, Shimanuki H, Kumakiri J, Kinoshita K. Recurrence rate of endometriomas following a laparoscopic cistectomy. Acta Obstet Gynecol Scand 2006; 85: 1120-4.
9. Koga K, Takemura Y, Osuga Y, et al. Recurrence of ovarian endometrioma after laparoscopic excision. Hum Reprod 2006; 21: 2171-4.
10. Porpora MG, Pallante D, Ferro A, et al. Pain and ovarian endometrioma recurrence after laparoscopic treatment of endometriosis: a long-term prospective study. Fertil Steril 2010; 93: 716-21.
11. Shakiba K, Bena JF, McGill KM, Minger J, Falcone T. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet Gynecol 2008; 111: 1285-92.
12. Vercellini P, Fedele L, Aimi G, De Giorgi O, Consonni D, Crosignani PG. Reproductive performance, pain recurrence and disease relapse after conservative surgical tratment for endometriosis: the predictive value of the current classification system. Hum Reprod 2006; 21: 2679-85.
13. Vercellini P, Somigliana E, Daguati R, ViganoP, Meroni F, Crosignani PG. Postoperative oral contraceptive exposure and risk of endometrioma recurrence. Am J Obstet Gynecol 2008; 198:404. e1-504.e5.
14. Bedaiwy MA, Falcone T. Peritoneal fluid environment in endometriosis. Clinicopathological implications. Minerva Ginecol 2003; 55: 333-45.
15. Bedaiwy MA, Falcone T. Laboratory testing for endometriosis. Clin Chim Acta 2004; 340: 41-56.
16. Mol BW, Mayram N, Lijmer JG, et al. The performance of CA 125 measurement in the detection of endometriosis: A meta-analysis. Fertil Steril 1998; 70: 1101.
17. Ozaksit G, Caglar T, Cicek N, Kuscu E, Batioglu S, Gokmen O. Serum CA 125 levels before, during and after treatment for endometriosis. Int J Gynaecol Obstet 1995; 50: 269-73.
18. Acien P, Shaw RW, Irvine L, Burford G, Gardner R. CA 125 levels in endometriosis patients before, during and after treatment with danazol or LHRH agonists. Eur J Obstet Gynecol Reprod Biol 1989; 32: 241-6.
19. Lanzone A, Fulghesu AM, Guida C, Muscatello R, Ca ruso A, Mancuso S. Serum CA125 levels do not depend on ovarian steroidogenesis. Fertil Steril 1990; 54: 415-8.
20. Jager W, Diedrich K, Wildt L. Elevated levels of CA125 in serum of patients' suffering from ovarian hyperstimulation syndrome. Fertil Steril 1987; 48: 675-8.
21. Zeimet AG, Muller-Holzner E, Marth C, Daxenbichler G, Dapunt O. Tumor marker CA125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle. Fertil Steril 1993; 59: 1028-35.
22. Koninckx PR, Riittinen L, Seppala M, Cornillie FJ. CA- 125 and placental protein 14 concentrations in plasma and peritoneal fluid of women with deeply infiltrating pelvic endometriosis. Fertil Steril 1992; 57: 523-30.
23. Olive DL. Empirical therapy with leuprorelin acetate for endometriosis in the United States. Drugs Today (Barc) 2005; 41 Suppl A: 5-10.
24. Khan KN, Kitajima M, Hiraki K, et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod 2010; 25: 642-53.
25. Pittaway DE, Fayez JA. Serum CA-125 antigen levels increase during menses. Am J Obstet Gynecol 1987; 156: 75-6.
26. Masahashi T, Matsuzawa K, Ohsawa M, Narita O, Asai T, Ishihara M. Serum CA 125 levels in patients with endometriosis: changes in CA 125 levels during menstruation. Obstet Gynecol 1988; 72: 328-31.
27. Hornstein MD, Thomas PP, Gleason RE, Barbieri RL. Menstrual cyclicity of CA-125 in patients with endometriosis. Fertil Steril 1992; 58: 279-83.
28. O'Shaughnessy A, Check JH, Nowroozi K, Lurie D. CA125 levels measured in different phases of the menstrual cycle in screening for endometriosis. Obstet Gynecol 1993; 81: 99-103.
29. Stones RW, Mountfield J. Interventions for treating chronic pelvic pain in women. Cochrane Database Syst Rev 2009.
30. Gambone JC, Mittman B, Munro M, Scialli A, Winkel CA. Consensus statement for the management of chronic pelvic pain and endometriosis: Proceedings of an expert- panel consensus process. Fertil Steril 2002; 78: 961-72.
31. Wheeler JM, Knittle JD, Miller JD. Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results. Am J Obstet Gynecol 1992; 167: 1367-71.
32. Gerhard I, Schindler AE, Bühler K, et al. Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study. Clin Ther 1992;14 Suppl A: 3-16.
33. Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, doubleblind study. Lupron Study Group. Fertil Steril 1990; 54: 419-27.
34. van der Spuy ZM, Wood M, Fieggen G, Hendricks MS. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues. S Afr Med J 1993; 83: 510-3.
35. Cetin T, Vardar MA, Demir C, Burgut R. Etiology of serum CA-125 in patients with endometriosis treated with a gonadotrophin-releasing hormone agonist (Buserelin). Gynecol Obstet Invest 1994; 38: 249-52.
36. Kafali H, Artunc H, Erdem M. Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle. Arch Gynecol Obstet 2007; 275: 175-7.
37. Howard FM. The role of laparoscopy in chronic pelvic pain: Promise and pitfalls. Obstet Gynecol Surv 1993; 48: 357-87.
38. Somigliana E, Vercellini P, Daguati R, Gianbattista E, Benaglia L, Fedele L. Effect of delaying post-operative conception after conservative surgery for endometriosis. Reprod Biomed Online 2010; 20: 410-5.